What is SpotitEarly?
SpotitEarly operates at the intersection of advanced biotechnology and medical innovation. Based in Israel, a global hub for life sciences, the company focuses on developing high-impact solutions that address critical gaps in current medical diagnostics. By leveraging sophisticated research and development, SpotitEarly aims to enhance patient outcomes through early detection and precision intervention. Its market position is characterized by a commitment to scientific rigor and a scalable business model that appeals to both venture capital firms and strategic industry partners. The company's focus on high-growth biotech segments positions it as a key player in the evolving healthcare technology ecosystem.
How much funding has SpotitEarly raised?
SpotitEarly has raised a total of $26.6M across 3 funding rounds:
Angel/Seed
$6.2M
Other Financing Round
$20.4M
Stock/Share Issuance
$10K
Angel/Seed (2022): $6.2M with participation from Hanaco
Other Financing Round (2025): $20.4M led by HANACO MEDICAL and The Menomadin Foundation
Stock/Share Issuance (2025): $10K, investors not publicly disclosed
Key Investors in SpotitEarly
Hanaco
Hanaco Ventures is a venture capital firm focused on supporting founders with big ideas and turning their visions into successful businesses. The company emphasizes decisive action and collaboration with entrepreneurs at various stages, from early visionaries to growth-stage leaders.
HANACO MEDICAL
HANACO MEDICAL is a pioneering manufacturer and seller of catheter medical devices, specializing in angiographic products and endoscopic devices aimed at healthcare professionals.
The Menomadin Foundation
The Menomadin Foundation employs a Blended Finance Approach through Strategic Philanthropy and Impact Investments to support disadvantaged communities and foster innovation in Israel.
What's next for SpotitEarly?
With the recent influx of capital, SpotitEarly is poised to scale its research initiatives and expand its commercial footprint. The strategic allocation of these funds will likely prioritize the advancement of its core product portfolio and the strengthening of its intellectual property moat. As the company moves forward, it will focus on navigating the complexities of clinical validation and regulatory approval, essential steps for long-term commercial viability. Furthermore, the involvement of specialized medical investors suggests a clear path toward integrating its innovations into existing clinical workflows. The company's future growth will be defined by its ability to translate scientific breakthroughs into tangible, market-ready medical solutions that address unmet needs in the global healthcare sector.
See full SpotitEarly company page
